Vinorelbine

Generic Name: Vinorelbine

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₄₅H_₅₄N_₄O_₈

CAS Number: 71486-22-1

Unique Ingredient Identifier: Q6C979R91Y

Background: Vinorelbine is an anti-mitotic chemotherapy drug that is used in the treatment of several types of malignancies, including breast cancer and non-small cell lung cancer (NSCLC) . It was initially approved in the USA in 1990's for the treatment of NSCLC .
...

Indication: Vinorelbine tartrate is indicated for adults in the treatment of advanced non-small cell lung cancer (NSCLC), as a single therapy or in combination with other chemotherapeutic drugs .

Used in relapsed or refractory Hodgkin lymphoma, in combination with other chemotherapy agents .
...

Associated Conditions: Locally Advanced Non-Small Cell Lung Cancer, Metastatic Breast Cancer, Metastatic Cervical Cancer, Metastatic Non-Small Cell Lung Cancer, Recurrent Cervical Cancer, Soft Tissue Sarcoma

Associated Therapies: -

Clinical Trials

Detect V / CHEVENDO (Chemo vs. Endo)

Phase 3

Active, not recruiting

Conditions: Metastatic Breast Cancer

Interventions: Drug: pertuzumab
Drug: Trastuzumab
Drug: eribulin
Drug: Letrozole
Drug: nab-Paclitaxel
Drug: Docetaxel
Drug: Paclitaxel
Drug: Vinorelbine
Drug: Exemestane
Drug: Capecitabine
Drug: Fulvestrant
Drug: Anastrozole
Drug: leuprorelin
Drug: Ribociclib
Drug: goserelin

First Posted Date: 2015-01-26

Last Posted Date: 2024-06-04

Lead Sponsor: Prof. Wolfgang Janni

Target Recruit Count: 271

Registration Number: NCT02344472

Locations: 🇩🇪
University Hospital Ulm Gynecology/Obstetrics, Ulm, Germany

Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus)

Phase 1

Terminated

Conditions: Pancreatic Cancer
Small Cell Lung Cancer
Ovarian
Sarcoma
Advanced Cancer
Breast Cancer

Interventions: Drug: Pembrolizumab
Drug: Gemcitabine
Drug: Liposomal Doxorubicin
Drug: Irinotecan
Drug: Docetaxel
Drug: Nab-paclitaxel
Drug: Vinorelbine

First Posted Date: 2015-01-06

Last Posted Date: 2018-07-02

Lead Sponsor: Western Regional Medical Center

Target Recruit Count: 81

Registration Number: NCT02331251

Locations: 🇺🇸
Cancer Treatment Center of America @ Western Regional Medical Center, Goodyear, Arizona, United States
🇺🇸
Western Regional Medical Center, Goodyear, Arizona, United States

Clinical Observation of S1 Capsule for Stage Ⅱ-ⅢA Non-small Cell Lung Cancer After Complete Resection

Phase 2

Conditions: Non-small Cell Lung Cancer Stage ⅢA
Non-small Cell Lung Cancer Stage Ⅱ

Interventions: Drug: S1 capsule
Drug: Vinorelbine

First Posted Date: 2014-08-22

Last Posted Date: 2014-08-22

Lead Sponsor: Hebei Medical University Fourth Hospital

Target Recruit Count: 100

Registration Number: NCT02223611

Locations: 🇨🇳
Jun Feng Liu, Shijiazhuang, Hebei, China

MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients

Phase 2

Terminated

Conditions: Breast Cancer
HER2 Positive Breast Cancer

Interventions: Drug: MM-302
Drug: Gemcitabine
Drug: Trastuzumab
Drug: Capecitabine
Drug: Vinorelbine

First Posted Date: 2014-08-11

Last Posted Date: 2017-01-06

Lead Sponsor: Merrimack Pharmaceuticals

Target Recruit Count: 113

Registration Number: NCT02213744

Locations: 🇺🇸
Tennessee Oncology, Chattanooga, Tennessee, United States
🇺🇸
Texas Oncology- Medical City, Dallas, Texas, United States
🇺🇸
Magee-Womens Hospital of UPMC, Pittsburgh, Pennsylvania, United States

and more 103 locations

Maintenance Low Dose Oral Navelbine In Patients With Non Small Cell Lung Cancer - MA.NI.LA Trial

Phase 2

Completed

Conditions: Non-small Cell Lung Cancer Stage IIIB
Non-small Cell Lung Cancer Stage IV

Interventions: Drug: Vinorelbine

First Posted Date: 2014-06-27

Last Posted Date: 2019-04-22

Lead Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Target Recruit Count: 120

Registration Number: NCT02176369

Locations: 🇮🇹
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, MI, Italy
🇮🇹
A.O. Ospedale di Circolo di Melegnano - P.O. Vizzolo Predabissi, Vizzolo Predabissi, MI, Italy
🇮🇹
Casa di Cura Dott. Pederzoli, Peschiera del Garda, VR, Italy

and more 17 locations

Maintenance Oral Vinorelbine or Observation After Vinorelbine-Docetaxel First Line Chemotherapy in Advanced Breast Ca

Phase 2

Conditions: Breast Cancer

Interventions: Drug: Vinorelbine-Docetaxel
Drug: Vinorelbine

First Posted Date: 2014-05-21

Last Posted Date: 2017-02-09

Lead Sponsor: Cancer Research Group - Collaborative Group, Beirut, Lebanon.

Target Recruit Count: 65

Registration Number: NCT02144194

Locations: 🇱🇧
Hammoud Hospital University Medical Center, Saida, Lebanon
🇱🇧
Hotel Dieu de France University Hospital, Achrafieh, Beirut, Lebanon

Vinorelbine in Mesothelioma

Phase 2

Completed

Conditions: Mesothelioma

Interventions: Other: Active Symptom Control
Drug: Vinorelbine

First Posted Date: 2014-05-15

Last Posted Date: 2021-10-12

Lead Sponsor: Wales Cancer Trials Unit

Target Recruit Count: 154

Registration Number: NCT02139904

Locations: 🇬🇧
Wales Cancer Trials Unit, Cardiff, United Kingdom

Study of Combination of PIGEV Before Autologous Stem Cell Transplant in Patients With Hodgkin's Lymphoma

Phase 1

Conditions: Hodgkin's Lymphoma

Interventions: Drug: panobinostat
Drug: Ifosfamide
Drug: Gemcitabine
Drug: Vinorelbine
Drug: Prednisolone

First Posted Date: 2013-06-24

Last Posted Date: 2014-01-29

Lead Sponsor: Armando Santoro, MD

Target Recruit Count: 24

Registration Number: NCT01884428

Locations: 🇮🇹
Istituto Clinico Humanitas, Rozzano, MI, Italy

Bendamustine, Gemcitabine and Vinorelbine (BeGEV) as Induction Therapy in Relapsed/Refractory Hodgkin's Lymphoma Patients

Phase 2

Conditions: Hodgkin's Lymphoma

Interventions: Drug: Bendamustine
Drug: Gemcitabine
Drug: Vinorelbine

First Posted Date: 2013-06-24

Last Posted Date: 2014-01-29

Lead Sponsor: Armando Santoro, MD

Target Recruit Count: 59

Registration Number: NCT01884441

Locations: 🇮🇹
Istituto Clinico Humanitas, Rozzano, MI, Italy

Study of Patient Preference for Oral or Intravenous Vinorelbine in the Treatment of Advanced NSCLC

Phase 4

Completed

Conditions: Non-small Cell Lung Cancer Metastatic

Interventions: Drug: Vinorelbine

First Posted Date: 2013-05-07

Last Posted Date: 2018-11-09

Lead Sponsor: Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori

Target Recruit Count: 120

Registration Number: NCT01848613

Locations: 🇮🇹
Irccs Irst, Meldola (FC), FC, Italy
🇮🇹
U.O. Oncologia Ospedale Civile Umberto I, Lugo, RA, Italy
🇮🇹
U.O. Oncologia Ospedale Civile degli Infermi, Faenza, RA, Italy

and more 5 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy